Not exact matches
Results showed that significantly more participants receiving the enhanced
placebo SMT
indicated good to excellent outcomes than those receiving standard
placebo SMT or no
treatment.
Importantly, these mice still had significant improvement in survival compared with immunized mice receiving
placebo treatment (average survival 9 d),
indicating that IFN - γ continues to play an important role in mortality in enhanced HLH disease.
Previously published findings
indicated that tPA
treatment led to better outcomes than
placebo in stroke patients treated from three hours to 4.5 hours post-stroke.